Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-3[[4(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[2,4-dimethyl-8-quinolinyl) oxy]methyl] phenyl]sulphonyl]-(2S)-2-pyrrolidinecarboxamide, di(methanesulfonate)

EU orphan designation number: EU/3/04/188   
Active ingredient: N-3[[4(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[2,4-dimethyl-8-quinolinyl) oxy]methyl] phenyl]sulphonyl]-(2S)-2-pyrrolidinecarboxamide, di(methanesulfonate)
Indication: Treatment of moderate and severe traumatic brain injury
Sponsor: Xytis Pharmaceuticals Limited
160 Queen Victoria Street, London EC4 V4QQ, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
26/02/2004 Orphan designation EMEA/OD/008/03 (2004)628 of 23/02/2004
04/04/2006 Transfer of orphan designation EMEA/OD/008/03/T/01 (2006)1613 of 10/04/2006